Study on Using MGRNOX Index to Guide Opioid Use During General Anesthesia for Laparoscopic Gallbladder Surgery

What this Trial Is About

Researchers are investigating the use of the MGRNOX index, derived from electroencephalogram EEG signals, to guide opioid pain management during general anesthesia in patients undergoing laparoscopic cholecystectomy. The study aims to see if this method can reduce opioid consumption, specifically remifentanil, compared to standard clinical care. Pain control during surgery is important to avoid complications related to too much or too little opioid use, and no current monitoring device is considered the definitive standard for guiding analgesic dosing. The trial compares two groups one where remifentanil dosing is adjusted to keep the MGRNOX index between 30 and 50 during surgery while also monitoring blood pressure and heart rate, and a control group where dosing adjustments are based on blood pressure and heart rate alone. Both groups receive anesthesia induction followed by intraoperative remifentanil administration with adjustments as needed. The study uses a randomized, triple-blind design to evaluate the effectiveness of this EEG-based monitoring device. Participants will be monitored throughout the surgery, with opioid consumption measured from anesthesia induction until the final wound closure. Additional assessments include pain scores one hour after extubation, incidences of unexpected events and complications, and use of sedative and vasoactive drugs during surgery. This comprehensive evaluation will help determine if the MGRNOX-guided approach can optimize opioid use and improve surgical outcomes. The study runs until May 2026 and is sponsored by Peking University Shenzhen Hospital.

Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients